News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation's Afatinib Receives Positive CHMP Opinion for Patients With EGFR Mutation Positive Lung Cancer in European Union


7/26/2013 10:24:19 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for afatinib – which has been submitted under the European Union brand name GIOTRIF®*. Afatinib is the first irreversible ErbB Family Blocker for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES